Mark J. Truty, M.D., performs clinical and translational research in pancreatic, hepatobiliary and gastrointestinal cancers. His clinical research is in the multidisciplinary surgical treatment of advanced gastrointestinal cancers, with a focus on novel preoperative therapies. He also serves as an institutional principal investigator on clinical trials.
Dr. Truty's translational and basic science work focuses on development of personalized animal models of individual patient tumors removed at surgery or at biopsy, with the goal of identifying effective screening and therapeutic biomarkers, assessing preclinical chemotherapeutic drug efficacy, and modeling of ideal treatment sequencing.
In addition, Dr. Truty is evaluating diagnostic and treatment strategies to improve perioperative outcomes of gastrointestinal surgical patients in an effort to minimize complications after surgery. Specifically, he is looking at inhibition of endogenous pancreaticoenteric catalytic enzymes that he has found are linked to a variety of disorders.
The focus of Dr. Truty's clinical practice is on patients with complex or advanced pancreatic, hepatobiliary and gastrointestinal malignancies.
- Pancreatic cancers
- Liver cancers — primary and metastatic
- Bile duct and gallbladder cancers
- Carcinoid tumors
- Gastric cancers
- Intestinal tumors
Significance to patient care
Dr. Truty's research may assist in earlier diagnosis as well as in the development of novel personalized systemic treatments and ideal treatment sequencing for various types of cancers. In addition, his work may potentially prevent and minimize postoperative complications in patients undergoing complex gastrointestinal cancer surgery in order to improve overall survival and quality of life.